Antiemetic Therapy

0
Pipeline Programs
1
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
non-interventionalN/A4 trials
Active Trials
NCT07456436Recruiting50Est. Nov 2027
NCT02921035CompletedEst. Jul 2020
NCT01125475Completed61
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Merck & Co.non-interventional
Merck & Co.non-interventional
Merck & Co.non-interventional
Merck & Co.non-interventional

Clinical Trials (4)

Total enrollment: 1,146 patients across 4 trials

NCT07456436Merck & Co.non-interventional

Data-Driven Strategies for Patient Engagement About Cancer Clinical Trials

Start: Nov 2024Est. completion: Nov 202750 patients
N/ARecruiting
NCT02921035Merck & Co.non-interventional

Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

Start: Jun 2016Est. completion: Jul 2020
N/ACompleted
NCT01125475Merck & Co.non-interventional

A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects

Start: Aug 201061 patients
N/ACompleted
NCT00911222Merck & Co.non-interventional

Epidemiological EMESIS-Registry

Start: Oct 2008Est. completion: Aug 20091,035 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 1,146 patients
1 companies competing in this space